Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across ABBOTT LABORATORIES's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
14 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays. approximately $21 billion equity value (about $23 billion including net debt).
Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.Robert B. Ford — Chairman and CEO, Abbott
With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.Abbott management — Exact Sciences completion release
St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation. approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt).
Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position.Miles D. White — Chairman and CEO, Abbott
Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient. $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value).
We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.Miles D. White — Chairman and CEO, Abbott
Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, position the combined company for strong growth.Namal Nawana — President and CEO, Alere
CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region. approximately $2.9 billion.
By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care.Abbott — CFR completion news release
Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint. EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments.
Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution. $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total).
Advanced Medical Optics is a leader in eye care, holding the number one position in LASIK surgical devices, number two in the cataract surgical device market and number three in the contact lens care market. $22.00 per share, approximately $2.8 billion including debt.
Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant. approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant).
Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises. $78.00 per share in cash (approximately $3.7 billion).
BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA). approximately $6.9 billion in cash.
Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease. $30.50 per share in cash (approximately $355 million).
i-STAT Corporation is a maker of handheld point-of-care blood analysis systems used at the patient's bedside. $15.35 per share in cash (approximately $392 million).
Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform. $27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net).
Cardiovascular Systems, Inc. (CSI) makes an atherectomy system used in treating peripheral and coronary artery disease, adding complementary technologies to Abbott's portfolio of vascular device offerings. $851 million ($20.00 per common share).
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI). CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.Abbott FY2023 10-K — Item 1 Business